BioCardia, Inc. announced the completion of enrollment and dosing in the low dose cohort of its Phase I/II CardiALLO™ trial, which aims to treat patients with ischemic heart failure of reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results